Shield Therapeutics: Reassessing the US opportunity

Shield Therapeutics plc (LON:STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in both Europe and the US. For various reasons, STX has been unable to secure a commercial partner for Accrufer in the US. Consequently, the board is now considering an STX-led launch option, thereby retaining all the US profits. Financial modelling shows the logic of this option, but it would necessitate financing the working capital requirements covering the next two years in the region of £25m-£30m.

  • Strategy: STX’s strategy has been to out-license commercialisation rights to partners with appropriate expertise in target markets. Although this strategy has been successful in Europe and China, the company has not been able to secure a satisfactory deal for the US, which has necessitated a re-think.
  • US options: During multiple US commercialisation discussions, potential partners have shared with STX management considerable intelligence about the US sales and marketing opportunity for Accrufer. Based on this information and its own research, the board has concluded that STX could launch Accrufer by itself.
  • Financial implications: Financial modelling suggests that retention of the commercialisation rights and profits to Accrufer in the US results in substantially higher returns for shareholders. However, to achieve this, the company will need additional working capital of £25m-£30m for the next two years.
  • Risks: Operationally, the main risk is that of execution, with little in-house commercial experience; however, STX has begun to address this by recruiting experienced US commercial managers. Finance will also be required, potentially through a combination of specialist debt and equity.
  • Investment summary: Subject to financing being available, the Shield Therapeutics-led option for Accrufer appears to be the best option for shareholders. The attributes and positioning off Accrufer are well-suited to the COVID-19 environment, eliminating the hospital attendance risk. The shares have over-reacted to the “lack of deal” news and should recover quickly once the uncertainty is removed.

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Shield Therapeutics: Positioned for growth and profitability

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been

    Hardman & Co

    Shield Therapeutics: Accrufer momentum building

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US, in July 2021, the

    Hardman & Co

    Shield Therapeutics: PBMs have bought in to Accrufer

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following the US launch of Accrufer® in July 2021, the

    Hardman & Co

    Shield Therapeutics: Focused on US market penetration

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Accrufer® has just been launched in the US by

    Hardman & Co

    Shield Therapeutics: Accrufer® launch on schedule

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in both

    Hardman & Co

    Shield Therapeutics US market offers a significant opportunity

    Shield Therapeutics plc (LON:STX) is the topic of conversation when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the company’s underperformance, explains how he thinks the shares could recover, how returns

    Hardman & Co

    Shield Therapeutics: Optimism over US deal

    Shield Therapeutics plc (LON:STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru/Accrufer has been approved by the regulators in both Europe

    Hardman & Co

    Shield Therapeutics Plc Good demand for Feraccru in Europe

    Shield Therapeutics (LON:STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this